Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations
Background Molecular tumor boards (MTBs) provide rational, genomics‐driven, patient‐tailored treatment recommendations. Worldwide, MTBs differ in terms of scope, composition, methods, and recommendations. This study aimed to assess differences in methods and agreement in treatment recommendations am...
Saved in:
| Published in | The oncologist (Dayton, Ohio) Vol. 26; no. 8; pp. e1347 - e1358 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Hoboken, USA
John Wiley & Sons, Inc
01.08.2021
Oxford University Press |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1083-7159 1549-490X 1549-490X |
| DOI | 10.1002/onco.13580 |
Cover
| Abstract | Background
Molecular tumor boards (MTBs) provide rational, genomics‐driven, patient‐tailored treatment recommendations. Worldwide, MTBs differ in terms of scope, composition, methods, and recommendations. This study aimed to assess differences in methods and agreement in treatment recommendations among MTBs from tertiary cancer referral centers in The Netherlands.
Materials and Methods
MTBs from all tertiary cancer referral centers in The Netherlands were invited to participate. A survey assessing scope, value, logistics, composition, decision‐making method, reporting, and registration of the MTBs was completed through on‐site interviews with members from each MTB. Targeted therapy recommendations were compared using 10 anonymized cases. Participating MTBs were asked to provide a treatment recommendation in accordance with their own methods. Agreement was based on which molecular alteration(s) was considered actionable with the next line of targeted therapy.
Results
Interviews with 24 members of eight MTBs revealed that all participating MTBs focused on rare or complex mutational cancer profiles, operated independently of cancer type–specific multidisciplinary teams, and consisted of at least (thoracic and/or medical) oncologists, pathologists, and clinical scientists in molecular pathology. Differences were the types of cancer discussed and the methods used to achieve a recommendation. Nevertheless, agreement among MTB recommendations, based on identified actionable molecular alteration(s), was high for the 10 evaluated cases (86%).
Conclusion
MTBs associated with tertiary cancer referral centers in The Netherlands are similar in setup and reach a high agreement in recommendations for rare or complex mutational cancer profiles. We propose a “Dutch MTB model” for an optimal, collaborative, and nationally aligned MTB workflow.
Implications for Practice
Interpretation of genomic analyses for optimal choice of target therapy for patients with cancer is becoming increasingly complex. A molecular tumor board (MTB) supports oncologists in rationalizing therapy options. However, there is no consensus on the most optimal setup for an MTB, which can affect the quality of recommendations. This study reveals that the eight MTBs associated with tertiary cancer referral centers in The Netherlands are similar in setup and reach a high agreement in recommendations for rare or complex mutational profiles. The Dutch MTB model is based on a collaborative and nationally aligned workflow with interinstitutional collaboration and data sharing.
Worldwide, molecular tumor boards (MTBs) differ in terms of scope, composition, methods, and recommendations. This article assesses differences in methods and agreement in treatment recommendations among MTBs from tertiary cancer referral centers in The Netherlands. |
|---|---|
| AbstractList | Worldwide, molecular tumor boards (MTBs) differ in terms of scope, composition, methods, and recommendations. This article assesses differences in methods and agreement in treatment recommendations among MTBs from tertiary cancer referral centers in The Netherlands. Molecular tumor boards (MTBs) provide rational, genomics-driven, patient-tailored treatment recommendations. Worldwide, MTBs differ in terms of scope, composition, methods, and recommendations. This study aimed to assess differences in methods and agreement in treatment recommendations among MTBs from tertiary cancer referral centers in The Netherlands.BACKGROUNDMolecular tumor boards (MTBs) provide rational, genomics-driven, patient-tailored treatment recommendations. Worldwide, MTBs differ in terms of scope, composition, methods, and recommendations. This study aimed to assess differences in methods and agreement in treatment recommendations among MTBs from tertiary cancer referral centers in The Netherlands.MTBs from all tertiary cancer referral centers in The Netherlands were invited to participate. A survey assessing scope, value, logistics, composition, decision-making method, reporting, and registration of the MTBs was completed through on-site interviews with members from each MTB. Targeted therapy recommendations were compared using 10 anonymized cases. Participating MTBs were asked to provide a treatment recommendation in accordance with their own methods. Agreement was based on which molecular alteration(s) was considered actionable with the next line of targeted therapy.MATERIALS AND METHODSMTBs from all tertiary cancer referral centers in The Netherlands were invited to participate. A survey assessing scope, value, logistics, composition, decision-making method, reporting, and registration of the MTBs was completed through on-site interviews with members from each MTB. Targeted therapy recommendations were compared using 10 anonymized cases. Participating MTBs were asked to provide a treatment recommendation in accordance with their own methods. Agreement was based on which molecular alteration(s) was considered actionable with the next line of targeted therapy.Interviews with 24 members of eight MTBs revealed that all participating MTBs focused on rare or complex mutational cancer profiles, operated independently of cancer type-specific multidisciplinary teams, and consisted of at least (thoracic and/or medical) oncologists, pathologists, and clinical scientists in molecular pathology. Differences were the types of cancer discussed and the methods used to achieve a recommendation. Nevertheless, agreement among MTB recommendations, based on identified actionable molecular alteration(s), was high for the 10 evaluated cases (86%).RESULTSInterviews with 24 members of eight MTBs revealed that all participating MTBs focused on rare or complex mutational cancer profiles, operated independently of cancer type-specific multidisciplinary teams, and consisted of at least (thoracic and/or medical) oncologists, pathologists, and clinical scientists in molecular pathology. Differences were the types of cancer discussed and the methods used to achieve a recommendation. Nevertheless, agreement among MTB recommendations, based on identified actionable molecular alteration(s), was high for the 10 evaluated cases (86%).MTBs associated with tertiary cancer referral centers in The Netherlands are similar in setup and reach a high agreement in recommendations for rare or complex mutational cancer profiles. We propose a "Dutch MTB model" for an optimal, collaborative, and nationally aligned MTB workflow.CONCLUSIONMTBs associated with tertiary cancer referral centers in The Netherlands are similar in setup and reach a high agreement in recommendations for rare or complex mutational cancer profiles. We propose a "Dutch MTB model" for an optimal, collaborative, and nationally aligned MTB workflow.Interpretation of genomic analyses for optimal choice of target therapy for patients with cancer is becoming increasingly complex. A molecular tumor board (MTB) supports oncologists in rationalizing therapy options. However, there is no consensus on the most optimal setup for an MTB, which can affect the quality of recommendations. This study reveals that the eight MTBs associated with tertiary cancer referral centers in The Netherlands are similar in setup and reach a high agreement in recommendations for rare or complex mutational profiles. The Dutch MTB model is based on a collaborative and nationally aligned workflow with interinstitutional collaboration and data sharing.IMPLICATIONS FOR PRACTICEInterpretation of genomic analyses for optimal choice of target therapy for patients with cancer is becoming increasingly complex. A molecular tumor board (MTB) supports oncologists in rationalizing therapy options. However, there is no consensus on the most optimal setup for an MTB, which can affect the quality of recommendations. This study reveals that the eight MTBs associated with tertiary cancer referral centers in The Netherlands are similar in setup and reach a high agreement in recommendations for rare or complex mutational profiles. The Dutch MTB model is based on a collaborative and nationally aligned workflow with interinstitutional collaboration and data sharing. Background Molecular tumor boards (MTBs) provide rational, genomics‐driven, patient‐tailored treatment recommendations. Worldwide, MTBs differ in terms of scope, composition, methods, and recommendations. This study aimed to assess differences in methods and agreement in treatment recommendations among MTBs from tertiary cancer referral centers in The Netherlands. Materials and Methods MTBs from all tertiary cancer referral centers in The Netherlands were invited to participate. A survey assessing scope, value, logistics, composition, decision‐making method, reporting, and registration of the MTBs was completed through on‐site interviews with members from each MTB. Targeted therapy recommendations were compared using 10 anonymized cases. Participating MTBs were asked to provide a treatment recommendation in accordance with their own methods. Agreement was based on which molecular alteration(s) was considered actionable with the next line of targeted therapy. Results Interviews with 24 members of eight MTBs revealed that all participating MTBs focused on rare or complex mutational cancer profiles, operated independently of cancer type–specific multidisciplinary teams, and consisted of at least (thoracic and/or medical) oncologists, pathologists, and clinical scientists in molecular pathology. Differences were the types of cancer discussed and the methods used to achieve a recommendation. Nevertheless, agreement among MTB recommendations, based on identified actionable molecular alteration(s), was high for the 10 evaluated cases (86%). Conclusion MTBs associated with tertiary cancer referral centers in The Netherlands are similar in setup and reach a high agreement in recommendations for rare or complex mutational cancer profiles. We propose a “Dutch MTB model” for an optimal, collaborative, and nationally aligned MTB workflow. Implications for Practice Interpretation of genomic analyses for optimal choice of target therapy for patients with cancer is becoming increasingly complex. A molecular tumor board (MTB) supports oncologists in rationalizing therapy options. However, there is no consensus on the most optimal setup for an MTB, which can affect the quality of recommendations. This study reveals that the eight MTBs associated with tertiary cancer referral centers in The Netherlands are similar in setup and reach a high agreement in recommendations for rare or complex mutational profiles. The Dutch MTB model is based on a collaborative and nationally aligned workflow with interinstitutional collaboration and data sharing. Worldwide, molecular tumor boards (MTBs) differ in terms of scope, composition, methods, and recommendations. This article assesses differences in methods and agreement in treatment recommendations among MTBs from tertiary cancer referral centers in The Netherlands. Molecular tumor boards (MTBs) provide rational, genomics-driven, patient-tailored treatment recommendations. Worldwide, MTBs differ in terms of scope, composition, methods, and recommendations. This study aimed to assess differences in methods and agreement in treatment recommendations among MTBs from tertiary cancer referral centers in The Netherlands. MTBs from all tertiary cancer referral centers in The Netherlands were invited to participate. A survey assessing scope, value, logistics, composition, decision-making method, reporting, and registration of the MTBs was completed through on-site interviews with members from each MTB. Targeted therapy recommendations were compared using 10 anonymized cases. Participating MTBs were asked to provide a treatment recommendation in accordance with their own methods. Agreement was based on which molecular alteration(s) was considered actionable with the next line of targeted therapy. Interviews with 24 members of eight MTBs revealed that all participating MTBs focused on rare or complex mutational cancer profiles, operated independently of cancer type-specific multidisciplinary teams, and consisted of at least (thoracic and/or medical) oncologists, pathologists, and clinical scientists in molecular pathology. Differences were the types of cancer discussed and the methods used to achieve a recommendation. Nevertheless, agreement among MTB recommendations, based on identified actionable molecular alteration(s), was high for the 10 evaluated cases (86%). MTBs associated with tertiary cancer referral centers in The Netherlands are similar in setup and reach a high agreement in recommendations for rare or complex mutational cancer profiles. We propose a "Dutch MTB model" for an optimal, collaborative, and nationally aligned MTB workflow. Interpretation of genomic analyses for optimal choice of target therapy for patients with cancer is becoming increasingly complex. A molecular tumor board (MTB) supports oncologists in rationalizing therapy options. However, there is no consensus on the most optimal setup for an MTB, which can affect the quality of recommendations. This study reveals that the eight MTBs associated with tertiary cancer referral centers in The Netherlands are similar in setup and reach a high agreement in recommendations for rare or complex mutational profiles. The Dutch MTB model is based on a collaborative and nationally aligned workflow with interinstitutional collaboration and data sharing. Background. Molecular tumor boards (MTBs) provide rational, genomics-driven, patient-tailored treatment recommendations. Worldwide, MTBs differ in terms of scope, composition, methods, and recommendations. This study aimed to assess differences in methods and agreement in treatment recommendations among MTBs from tertiary cancer referral centers in The Netherlands. Materials and Methods. MTBs from all tertiary cancer referral centers in The Netherlands were invited to participate. A survey assessing scope, value, logistics, composition, decision-making method, reporting, and registration of the MTBs was completed through on-site interviews with members from each MTB. Targeted therapy recommendations were compared using 10 anonymized cases. Participating MTBs were asked to provide a treatment recommendation in accordance with their own methods. Agreement was based on which molecular alteration(s) was considered actionable with the next line of targeted therapy. Results. Interviews with 24 members of eight MTBs revealed that all participating MTBs focused on rare or complex mutational cancer profiles, operated independently of cancer type-specific multidisciplinary teams, and consisted of at least (thoracic and/or medical) oncologists, pathologists, and clinical scientists in molecular pathology. Differences were the types of cancer discussed and the methods used to achieve a recommendation. Nevertheless, agreement among MTB recommendations, based on identified actionable molecular alteration(s), was high for the 10 evaluated cases (86%). Conclusion. MTBs associated with tertiary cancer referral centers in The Netherlands are similar in setup and reach a high agreement in recommendations for rare or complex mutational cancer profiles. We propose a "Dutch MTB model" for an optimal, collaborative, and nationally aligned MTB workflow. Key Words. Molecular tumor board * Rare mutations * Molecular diagnostics * Decisionmaking * Multidisciplinary |
| Audience | Professional Academic |
| Author | Speel, Ernst‐Jan M. Leng, Wendy W.J. Groen, Harry J.M. Mehra, Niven Wezel, Tom Kempen, Léon C. Ligtenberg, Marjolijn J.L. Gelderblom, Hans Lindert, Anne S.R. Piet, Berber Willems, Stefan M. Kroeze, Leonie I. Hashemi, Sayed M.S. Dinjens, Winand N.M. Langen, Adrianus J. Boelens, Mirjam C. Monkhorst, Kim Meijers, Ruud W.J. Thüsen, Jan H. Hendriks, Lizza E. Timens, Wim Grünberg, Katrien Wekken, Anthonie J. Koopman, Bart Radonic, Teodora Solleveld, Nienke Schuuring, Ed Heideman, Daniëlle A.M. Paats, Marthe S. Theunissen, Tom E. Elst, Arja |
| AuthorAffiliation | 2 Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen Groningen The Netherlands 10 Department of Pathology, Erasmus Medical Center, University Medical Center Rotterdam Rotterdam The Netherlands 16 Department of Pulmonology, University Medical Center Utrecht Utrecht The Netherlands 3 Department of Pathology, Radboud University Medical Center Nijmegen The Netherlands 9 Department of Pulmonary Medicine, Erasmus Medical Center, University Medical Center Rotterdam Rotterdam The Netherlands 4 Department of Human Genetics, Radboud University Medical Center Nijmegen The Netherlands 15 Department of Pathology, University Medical Center Utrecht Utrecht The Netherlands 5 Department of Medical Oncology, Radboud University Medical Center Nijmegen The Netherlands 1 Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen Groningen The Netherlands 11 Department of Pathology, Leiden University Medical Center Leiden The |
| AuthorAffiliation_xml | – name: 10 Department of Pathology, Erasmus Medical Center, University Medical Center Rotterdam Rotterdam The Netherlands – name: 16 Department of Pulmonology, University Medical Center Utrecht Utrecht The Netherlands – name: 9 Department of Pulmonary Medicine, Erasmus Medical Center, University Medical Center Rotterdam Rotterdam The Netherlands – name: 5 Department of Medical Oncology, Radboud University Medical Center Nijmegen The Netherlands – name: 18 Department of Pulmonary Diseases, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam Amsterdam The Netherlands – name: 13 Department of Pulmonary Diseases, GROW‐School for Oncology and Developmental Biology, Maastricht University Medical Center Maastricht The Netherlands – name: 7 Department of Pathology, Netherlands Cancer Institute Amsterdam The Netherlands – name: 1 Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen Groningen The Netherlands – name: 6 Department of Pulmonary Diseases, Radboud University Medical Center Nijmegen The Netherlands – name: 2 Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen Groningen The Netherlands – name: 12 Department of Medical Oncology, Leiden University Medical Center Leiden The Netherlands – name: 17 Department of Pathology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam Amsterdam The Netherlands – name: 3 Department of Pathology, Radboud University Medical Center Nijmegen The Netherlands – name: 8 Department of Thoracic Oncology, Netherlands Cancer Institute Amsterdam The Netherlands – name: 15 Department of Pathology, University Medical Center Utrecht Utrecht The Netherlands – name: 14 Department of Pathology, GROW‐School for Oncology and Developmental Biology, Maastricht University Medical Center Maastricht The Netherlands – name: 11 Department of Pathology, Leiden University Medical Center Leiden The Netherlands – name: 4 Department of Human Genetics, Radboud University Medical Center Nijmegen The Netherlands |
| Author_xml | – sequence: 1 givenname: Bart orcidid: 0000-0003-0873-9638 surname: Koopman fullname: Koopman, Bart organization: Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen – sequence: 2 givenname: Harry J.M. surname: Groen fullname: Groen, Harry J.M. organization: Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen – sequence: 3 givenname: Marjolijn J.L. surname: Ligtenberg fullname: Ligtenberg, Marjolijn J.L. organization: Department of Human Genetics, Radboud University Medical Center – sequence: 4 givenname: Katrien surname: Grünberg fullname: Grünberg, Katrien organization: Department of Pathology, Radboud University Medical Center – sequence: 5 givenname: Kim surname: Monkhorst fullname: Monkhorst, Kim organization: Department of Pathology, Netherlands Cancer Institute – sequence: 6 givenname: Adrianus J. surname: Langen fullname: Langen, Adrianus J. organization: Department of Thoracic Oncology, Netherlands Cancer Institute – sequence: 7 givenname: Mirjam C. surname: Boelens fullname: Boelens, Mirjam C. organization: Department of Pathology, Netherlands Cancer Institute – sequence: 8 givenname: Marthe S. surname: Paats fullname: Paats, Marthe S. organization: Department of Pulmonary Medicine, Erasmus Medical Center, University Medical Center Rotterdam – sequence: 9 givenname: Jan H. surname: Thüsen fullname: Thüsen, Jan H. organization: Department of Pathology, Erasmus Medical Center, University Medical Center Rotterdam – sequence: 10 givenname: Winand N.M. surname: Dinjens fullname: Dinjens, Winand N.M. organization: Department of Pathology, Erasmus Medical Center, University Medical Center Rotterdam – sequence: 11 givenname: Nienke surname: Solleveld fullname: Solleveld, Nienke organization: Department of Pathology, Leiden University Medical Center – sequence: 12 givenname: Tom surname: Wezel fullname: Wezel, Tom organization: Department of Pathology, Leiden University Medical Center – sequence: 13 givenname: Hans surname: Gelderblom fullname: Gelderblom, Hans organization: Department of Medical Oncology, Leiden University Medical Center – sequence: 14 givenname: Lizza E. surname: Hendriks fullname: Hendriks, Lizza E. organization: Department of Pulmonary Diseases, GROW‐School for Oncology and Developmental Biology, Maastricht University Medical Center – sequence: 15 givenname: Ernst‐Jan M. surname: Speel fullname: Speel, Ernst‐Jan M. organization: Department of Pathology, GROW‐School for Oncology and Developmental Biology, Maastricht University Medical Center – sequence: 16 givenname: Tom E. surname: Theunissen fullname: Theunissen, Tom E. organization: Department of Pathology, GROW‐School for Oncology and Developmental Biology, Maastricht University Medical Center – sequence: 17 givenname: Leonie I. surname: Kroeze fullname: Kroeze, Leonie I. organization: Department of Pathology, Radboud University Medical Center – sequence: 18 givenname: Niven surname: Mehra fullname: Mehra, Niven organization: Department of Medical Oncology, Radboud University Medical Center – sequence: 19 givenname: Berber surname: Piet fullname: Piet, Berber organization: Department of Pulmonary Diseases, Radboud University Medical Center – sequence: 20 givenname: Anthonie J. surname: Wekken fullname: Wekken, Anthonie J. organization: Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen – sequence: 21 givenname: Arja surname: Elst fullname: Elst, Arja organization: Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen – sequence: 22 givenname: Wim surname: Timens fullname: Timens, Wim organization: Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen – sequence: 23 givenname: Stefan M. surname: Willems fullname: Willems, Stefan M. organization: Department of Pathology, University Medical Center Utrecht – sequence: 24 givenname: Ruud W.J. surname: Meijers fullname: Meijers, Ruud W.J. organization: Department of Pathology, University Medical Center Utrecht – sequence: 25 givenname: Wendy W.J. surname: Leng fullname: Leng, Wendy W.J. organization: Department of Pathology, University Medical Center Utrecht – sequence: 26 givenname: Anne S.R. surname: Lindert fullname: Lindert, Anne S.R. organization: Department of Pulmonology, University Medical Center Utrecht – sequence: 27 givenname: Teodora surname: Radonic fullname: Radonic, Teodora organization: Department of Pathology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam – sequence: 28 givenname: Sayed M.S. surname: Hashemi fullname: Hashemi, Sayed M.S. organization: Department of Pulmonary Diseases, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam – sequence: 29 givenname: Daniëlle A.M. surname: Heideman fullname: Heideman, Daniëlle A.M. organization: Department of Pathology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam – sequence: 30 givenname: Ed surname: Schuuring fullname: Schuuring, Ed organization: Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen – sequence: 31 givenname: Léon C. orcidid: 0000-0003-0646-0705 surname: Kempen fullname: Kempen, Léon C. email: l.van.kempen@umcg.nl organization: Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33111480$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kt-KEzEUxoOsuLvVGx9AAt6I7NRkMpnJ7IWw1r-w3YJU8C6kyZk2MpPUZEbpM_jSZtquuLJILnKS_L6Pc3LOOTpx3gFCTymZUkLyV95pP6WMC_IAnVFe1FlRk68nKSaCZRXl9Sk6j_EbISlk-SN0yhiltBDkDP2aD21vNbgeAp75bquCjd5h3-C5b0EPrQp4OXQ-4DdeBROxdXi5AXwD_QZCq5yJl_gtNNbZ3np3sTfx8XiYJ8qbeIETh5cqrKEHM-qD2u7wZ9C-68AZNdLxMXrYqDbCk-M-QV_ev1vOPmbXiw-fZlfXmeackazMS8q1KKuVMLxsKpHndV6T0tR8xaAUildNIRQQymowihLIc1aaipIVFYIZNkGvD77bYdWBGYsPqpXbYDsVdtIrK---OLuRa_9DClbkPFlM0IujQfDfB4i97GzU0KbfAD9EmRec06ouaJXQ5wd0rVqQ1jU-OeoRl1eVSCmSmrBETe-h0jLQWZ263dh0f0fw7O8S_uR-29gEkAOgg48xQCO17fffnJxtKymR4-zIcXbkfnaS5OU_klvXe2F6gH-mzHb_IeXiZrY4aH4DQkjVBg |
| CitedBy_id | crossref_primary_10_1093_oncolo_oyae206 crossref_primary_10_1002_onco_13936 crossref_primary_10_1186_s12916_022_02560_5 crossref_primary_10_3390_cancers13143641 crossref_primary_10_1016_j_acpath_2022_100056 crossref_primary_10_1200_PO_23_00615 crossref_primary_10_1016_j_critrevonc_2022_103642 crossref_primary_10_1016_j_critrevonc_2024_104379 crossref_primary_10_1007_s12254_024_00978_6 crossref_primary_10_1001_jamaoncol_2023_5120 crossref_primary_10_14341_probl13220 crossref_primary_10_1186_s12943_022_01551_7 crossref_primary_10_1016_j_heliyon_2024_e30303 crossref_primary_10_1016_j_lungcan_2025_108107 crossref_primary_10_2196_53627 crossref_primary_10_3390_hematolrep15020025 crossref_primary_10_1186_s12967_023_04673_8 crossref_primary_10_3904_kjm_2022_97_5_319 crossref_primary_10_1016_j_jcpo_2024_100515 crossref_primary_10_1016_j_lungcan_2022_01_009 crossref_primary_10_3390_jpm11070654 crossref_primary_10_1007_s00292_021_00938_5 crossref_primary_10_1186_s13046_022_02512_0 crossref_primary_10_3390_curroncol30020191 crossref_primary_10_1002_1878_0261_13562 crossref_primary_10_1016_j_lanepe_2024_100838 crossref_primary_10_1038_s41416_021_01663_9 crossref_primary_10_1016_j_cmpb_2023_107697 crossref_primary_10_1200_PO_22_00132 crossref_primary_10_1007_s11060_024_04568_8 crossref_primary_10_1001_jamanetworkopen_2022_45081 crossref_primary_10_1186_s12911_024_02821_8 |
| Cites_doi | 10.1093/nar/29.1.308 10.1093/annonc/mdz080 10.1634/theoncologist.2013-0405 10.1007/s00428-016-2025-7 10.1002/ijc.32358 10.1093/nar/gkt1113 10.1093/annonc/mdy263 10.18632/oncotarget.16057 10.18632/oncotarget.18471 10.1093/nar/gky1113 10.1016/j.bbrc.2006.11.091 10.1038/s41416-019-0489-3 10.18632/oncotarget.8391 10.1136/esmoopen-2018-000398 10.1634/theoncologist.2016-0195 10.1186/s40246-016-0061-7 10.1038/nature15393 10.1200/JCO.2012.46.8934 10.3389/fped.2017.00265 10.1016/j.jmoldx.2016.10.002 10.1093/nar/gkw1121 10.1093/annonc/mdx528 10.1136/esmoopen-2018-000469 10.1200/PO.20.00008 10.1634/theoncologist.2015-0097 10.1136/esmoopen-2018-000339 10.1002/pbc.26002 10.1038/sj.bjc.6605534 10.1111/imj.13806 10.1038/s41586-019-1600-x |
| ContentType | Journal Article |
| Copyright | 2020 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press. COPYRIGHT 2021 Oxford University Press |
| Copyright_xml | – notice: 2020 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press. – notice: COPYRIGHT 2021 Oxford University Press |
| DBID | 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1002/onco.13580 |
| DatabaseName | Wiley Online Library Open Access (Activated by CARLI) CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access (Activated by CARLI) url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Molecular Tumor Boards in The Netherlands |
| EISSN | 1549-490X |
| EndPage | e1358 |
| ExternalDocumentID | PMC8342588 A780130903 33111480 10_1002_onco_13580 ONCO13580 |
| Genre | article Research Support, Non-U.S. Gov't Multicenter Study Journal Article |
| GeographicLocations | Netherlands United Kingdom United States Switzerland Germany |
| GeographicLocations_xml | – name: Netherlands – name: United Kingdom – name: Switzerland – name: Germany – name: United States |
| GrantInformation_xml | – fundername: ZonMw funderid: 846001001 – fundername: ; grantid: 846001001 |
| GroupedDBID | --- 0R~ 123 18M 1OC 24P 2WC 36B 4.4 53G 5VS AAPXW AAVAP AAWTL AAZKR ABEJV ABPTD ABXVV ACXQS ADBBV ADXAS AEGXH AENEX AJAOE ALMA_UNASSIGNED_HOLDINGS AMNDL AOIJS BAWUL BFHJK CS3 DCZOG DIK DU5 E3Z EBD EBS EJD EMB EMOBN F5P FRP GROUPED_DOAJ GX1 H13 HYE HZ~ IAO IHR INH ITC LUTES LYRES O9- OK1 P2P P2W RAO RHF RHI ROL ROX RPM SUPJJ SV3 TOX TR2 UDS W2D W8F WIN WOHZO WOQ WOW XSB ZZTAW AAFWJ AAYXX ABGNP AFPKN CITATION OVT 7X7 88E 8FI 8FJ AAMMB ABUWG AEFGJ AFKRA AGXDD AIDQK AIDYY BENPR CCPQU CGR CUY CVF ECM EIF FYUFA HMCUK M1P NPM PHGZM PHGZT PIMPY PJZUB PPXIY PSQYO UKHRP 7X8 5PM |
| ID | FETCH-LOGICAL-c5530-62615c867b8d56f782292906d95b3e68a57f48ae0139eda10e2236d710b1883d3 |
| IEDL.DBID | 24P |
| ISSN | 1083-7159 1549-490X |
| IngestDate | Thu Aug 21 14:38:06 EDT 2025 Fri Sep 05 09:56:31 EDT 2025 Tue Jun 17 22:23:45 EDT 2025 Tue Jun 10 21:15:21 EDT 2025 Mon Jul 21 05:22:57 EDT 2025 Tue Jul 01 01:17:20 EDT 2025 Thu Apr 24 22:56:09 EDT 2025 Wed Jan 22 16:28:17 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Keywords | Molecular diagnostics Rare mutations Decision making Multidisciplinary Molecular tumor board |
| Language | English |
| License | Attribution-NonCommercial-NoDerivs https://creativecommons.org/licenses/by-nc-nd/4.0 2020 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5530-62615c867b8d56f782292906d95b3e68a57f48ae0139eda10e2236d710b1883d3 |
| Notes | . Disclosures of potential conflicts of interest may be found at the end of this article ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Disclosures of potential conflicts of interest may be found at the end of this article. |
| ORCID | 0000-0003-0873-9638 0000-0003-0646-0705 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fonco.13580 |
| PMID | 33111480 |
| PQID | 2455179417 |
| PQPubID | 23479 |
| PageCount | 12 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8342588 proquest_miscellaneous_2455179417 gale_infotracmisc_A780130903 gale_infotracacademiconefile_A780130903 pubmed_primary_33111480 crossref_citationtrail_10_1002_onco_13580 crossref_primary_10_1002_onco_13580 wiley_primary_10_1002_onco_13580_ONCO13580 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | August 2021 |
| PublicationDateYYYYMMDD | 2021-08-01 |
| PublicationDate_xml | – month: 08 year: 2021 text: August 2021 |
| PublicationDecade | 2020 |
| PublicationPlace | Hoboken, USA |
| PublicationPlace_xml | – name: Hoboken, USA – name: England |
| PublicationTitle | The oncologist (Dayton, Ohio) |
| PublicationTitleAlternate | Oncologist |
| PublicationYear | 2021 |
| Publisher | John Wiley & Sons, Inc Oxford University Press |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: Oxford University Press |
| References | 2017; 5 2018; 29 2017; 8 2017; 1 2019; 4 2017; 2017 2019; 30 2017; 28 2017; 22 2017; 45 2010; 102 2016; 10 2007 2017; 470 2004 2015; 526 2001; 29 2018; 48 2019; 145 2019; 121 2014; 42 2016; 7 2020; 4 2018; 3 2018; 2 2020 2015; 20 2007; 352 2013; 31 2019; 47 2016; 63 2016 2017; 19 2014; 19 6 2019; 574 Universitair Medisch Centrum Groningen (2022011918031981700_onco13580-bib-0021) 2007 Rieke (2022011918031981700_onco13580-bib-0019) 2018; 2 Knepper (2022011918031981700_onco13580-bib-0010) 2017; 22 PubMed. U.S. National Library of Medicine Web site (2022011918031981700_onco13580-bib-0033) Rolfo (2022011918031981700_onco13580-bib-0015) 2018; 3 Gao (2022011918031981700_onco13580-bib-0026); 6 Patterson (2022011918031981700_onco13580-bib-0031) 2016; 10 Chakravarty (2022011918031981700_onco13580-bib-0032) 2017; 2017 Garraway (2022011918031981700_onco13580-bib-0001) 2013; 31 Harada (2022011918031981700_onco13580-bib-0008) 2017; 8 Marks (2022011918031981700_onco13580-bib-0012) 2017; 5 Willemsen (2022011918031981700_onco13580-bib-0003) 2019; 121 Leichsenring (2022011918031981700_onco13580-bib-0043) 2019; 145 Trédan (2022011918031981700_onco13580-bib-0018) 2019; 30 1000 Genomes Project Consortium (2022011918031981700_onco13580-bib-0025) 2015; 526 Forbes (2022011918031981700_onco13580-bib-0028) 2017; 45 Akagi (2022011918031981700_onco13580-bib-0038) 2007; 352 Mateo (2022011918031981700_onco13580-bib-0041) 2018; 29 Nederlandse Vereniging voor Medische Oncologie (NVMO) (2022011918031981700_onco13580-bib-0037) Health RI: Enabling data driven health (2022011918031981700_onco13580-bib-0040) Schwaederle (2022011918031981700_onco13580-bib-0016) 2014; 19 Kaderbhai (2022011918031981700_onco13580-bib-0009) 2016; 7 Nederlandse Vereniging voor Pathologie (NVVP) (2022011918031981700_onco13580-bib-0035) Ortiz (2022011918031981700_onco13580-bib-0014) 2016; 63 Cunningham (2022011918031981700_onco13580-bib-0030) 2019; 47 Basse (2022011918031981700_onco13580-bib-0005) 2018; 3 Dutch Federation of Biomedical Scientific Societies (2022011918031981700_onco13580-bib-0022) 2004 Nederlandse Vereniging voor Artsen voor Longziekten en Tuberculose (2022011918031981700_onco13580-bib-0023) 2020 Tafe (2022011918031981700_onco13580-bib-0017) 2015; 20 Sherry (2022011918031981700_onco13580-bib-0029) 2001; 29 Nederlandse Vereniging van Artsen voor Longziekten en Tuberculose (NVALT) (2022011918031981700_onco13580-bib-0036) Li (2022011918031981700_onco13580-bib-0042) 2017; 19 Velden (2022011918031981700_onco13580-bib-0002) 2017; 28 Moore (2022011918031981700_onco13580-bib-0013) 2019; 4 Bryce (2022011918031981700_onco13580-bib-0006) 2017; 8 Velden (2022011918031981700_onco13580-bib-0024) 2019; 574 Smith (2022011918031981700_onco13580-bib-0039) 2010; 102 Koopman (2022011918031981700_onco13580-bib-0004) 2020; 4 Dalton (2022011918031981700_onco13580-bib-0007) 2017; 1 Nederlandse organisatie voor gezondheidsonderzoek en zorginnovatie (ZonMW) (2022011918031981700_onco13580-bib-0020) 2016 Lee (2022011918031981700_onco13580-bib-0011) 2018; 48 Landrum (2022011918031981700_onco13580-bib-0027) 2014; 42 Deans (2022011918031981700_onco13580-bib-0034) 2017; 470 |
| References_xml | – volume: 7 start-page: 24860 year: 2016 end-page: 24870 article-title: Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer publication-title: Oncotarget – volume: 10 start-page: 4 year: 2016 article-title: The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies publication-title: Hum Genomics – volume: 5 start-page: 265 year: 2017 article-title: Precision medicine in children and young adults with hematologic malignancies and blood disorders: The Columbia University experience publication-title: Front Pediatr – volume: 30 start-page: 757 year: 2019 end-page: 765 article-title: Molecular screening program to select molecular‐based recommended therapies for metastatic cancer patients: Analysis from the ProfiLER trial publication-title: Ann Oncol – volume: 102 start-page: 693 year: 2010 end-page: 703 article-title: Activating K‐Ras mutations outwith “hotspot” codons in sporadic colorectal tumours ‐ implications for personalised cancer medicine publication-title: Br J Cancer – volume: 19 start-page: 4 year: 2017 end-page: 23 article-title: Standards and guidelines for the interpretation and reporting of sequence variants in cancer: A joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists publication-title: J Mol Diagn – volume: 121 start-page: 34 year: 2019 end-page: 36 article-title: Molecular tumour boards and molecular diagnostics for patients with cancer in The Netherlands: Experiences, challenges, and aspirations publication-title: Br J Cancer – year: 2007 – volume: 45 start-page: D777 year: 2017 end-page: D783 article-title: COSMIC: Somatic cancer genetics at high‐resolution publication-title: Nucleic Acids Res – volume: 20 start-page: 1011 year: 2015 end-page: 1018 article-title: Implementation of a molecular tumor board: The impact on treatment decisions for 35 patients evaluated at Dartmouth‐Hitchcock Medical Center publication-title: The Oncologist – volume: 29 start-page: 308 year: 2001 end-page: 311 article-title: dbSNP: The NCBI database of genetic variation publication-title: Nucleic Acids Res – volume: 145 start-page: 2996 year: 2019 end-page: 3010 article-title: Variant classification in precision oncology publication-title: Int J Cancer – volume: 2017 start-page: 513 year: 2017 end-page: 519 article-title: OncoKB: A precision oncology knowledge base publication-title: JCO Precis Oncol – year: 2016 – volume: 48 start-page: 786 year: 2018 end-page: 794 article-title: Exploring the feasibility and utility of exome‐scale tumour sequencing in a clinical setting publication-title: Intern Med J – volume: 2 year: 2018 article-title: Comparison of treatment recommendations by molecular tumor boards worldwide publication-title: JCO Precis Oncol – volume: 4 start-page: 393 year: 2020 end-page: 410 article-title: Relevance and effectiveness of molecular tumor board recommendations for patients with non–small‐cell lung cancer with rare or complex mutational profiles publication-title: JCO Precis Oncol – volume: 8 start-page: 57845 year: 2017 end-page: 57854 article-title: Implementation and utilization of the molecular tumor board to guide precision medicine publication-title: Oncotarget – volume: 526 start-page: 68 year: 2015 end-page: 74 article-title: A global reference for human genetic variation publication-title: Nature – volume: 8 start-page: 27145 year: 2017 end-page: 27154 article-title: Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery publication-title: Oncotarget – volume: 19 start-page: 631 year: 2014 end-page: 636 article-title: Molecular tumor board: The University of California‐San Diego Moores Cancer Center experience publication-title: The Oncologist – volume: 29 start-page: 1895 year: 2018 end-page: 1902 article-title: A framework to rank genomic alterations as targets for cancer precision medicine: The ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) publication-title: Ann Oncol – volume: 470 start-page: 5 year: 2017 end-page: 20 article-title: Integration of next‐generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL publication-title: Virchows Arch – volume: 4 year: 2019 article-title: Prospective analysis of 895 patients on a UK genomics review board publication-title: ESMO Open – volume: 3 year: 2018 article-title: Multidisciplinary molecular tumour board: A tool to improve clinical practice and selection accrual for clinical trials in patients with cancer publication-title: ESMO Open – volume: 47 start-page: D745 year: 2019 end-page: D751 article-title: Ensembl 2019 publication-title: Nucleic Acids Res – volume: 6 start-page: 2013 article-title: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal publication-title: Sci Signal – volume: 63 start-page: 1368 year: 2016 end-page: 1374 article-title: Integrating genomics into clinical pediatric oncology using the molecular tumor board at the Memorial Sloan Kettering Cancer Center publication-title: Pediatr Blood Cancer – volume: 3 year: 2018 article-title: Relevance of a molecular tumour board (MTB) for patients’ enrolment in clinical trials: Experience of the Institut Curie publication-title: ESMO Open – year: 2004 – year: 2020 – volume: 31 start-page: 1806 year: 2013 end-page: 1814 article-title: Genomics‐driven oncology: Framework for an emerging paradigm publication-title: J Clin Oncol – volume: 1 year: 2017 article-title: Personalized medicine in the oncology clinic: Implementation and outcomes of the Johns Hopkins molecular tumor board publication-title: JCO Precis Oncol – volume: 352 start-page: 728 year: 2007 end-page: 32 article-title: Characterization of a novel oncogenic K‐ras mutation in colon cancer publication-title: Biochem Biophys Res Commun – volume: 574 start-page: 127 year: 2019 end-page: 131 article-title: The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs publication-title: Nature – volume: 42 start-page: D980 year: 2014 end-page: D985 article-title: ClinVar: Public archive of relationships among sequence variation and human phenotype publication-title: Nucleic Acids Res – volume: 22 start-page: 144 year: 2017 end-page: 151 article-title: Key lessons learned from Moffitt's molecular tumor board: The Clinical Genomics Action Committee experience publication-title: The Oncologist – volume: 28 start-page: 3070 year: 2017 end-page: 3075 article-title: Molecular tumor boards: Current practice and future needs publication-title: Ann Oncol – volume-title: Behandeling patiënten met een zeldzame mutatie bij NSCLC year: 2020 ident: 2022011918031981700_onco13580-bib-0023 – volume: 29 start-page: 308 year: 2001 ident: 2022011918031981700_onco13580-bib-0029 article-title: dbSNP: The NCBI database of genetic variation publication-title: Nucleic Acids Res doi: 10.1093/nar/29.1.308 – volume-title: Predictive Analysis for Therapy: PATH to Optimising Access to Personalised Cancer Therapy in The Netherlands year: 2016 ident: 2022011918031981700_onco13580-bib-0020 – volume-title: Research Code year: 2007 ident: 2022011918031981700_onco13580-bib-0021 – volume: 30 start-page: 757 year: 2019 ident: 2022011918031981700_onco13580-bib-0018 article-title: Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: Analysis from the ProfiLER trial publication-title: Ann Oncol doi: 10.1093/annonc/mdz080 – volume: 19 start-page: 631 year: 2014 ident: 2022011918031981700_onco13580-bib-0016 article-title: Molecular tumor board: The University of California-San Diego Moores Cancer Center experience publication-title: The Oncologist doi: 10.1634/theoncologist.2013-0405 – volume: 470 start-page: 5 year: 2017 ident: 2022011918031981700_onco13580-bib-0034 article-title: Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL publication-title: Virchows Arch doi: 10.1007/s00428-016-2025-7 – volume: 145 start-page: 2996 year: 2019 ident: 2022011918031981700_onco13580-bib-0043 article-title: Variant classification in precision oncology publication-title: Int J Cancer doi: 10.1002/ijc.32358 – ident: 2022011918031981700_onco13580-bib-0035 – volume: 42 start-page: D980 year: 2014 ident: 2022011918031981700_onco13580-bib-0027 article-title: ClinVar: Public archive of relationships among sequence variation and human phenotype publication-title: Nucleic Acids Res doi: 10.1093/nar/gkt1113 – volume: 29 start-page: 1895 year: 2018 ident: 2022011918031981700_onco13580-bib-0041 article-title: A framework to rank genomic alterations as targets for cancer precision medicine: The ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) publication-title: Ann Oncol doi: 10.1093/annonc/mdy263 – volume: 8 start-page: 27145 year: 2017 ident: 2022011918031981700_onco13580-bib-0006 article-title: Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery publication-title: Oncotarget doi: 10.18632/oncotarget.16057 – volume: 2 year: 2018 ident: 2022011918031981700_onco13580-bib-0019 article-title: Comparison of treatment recommendations by molecular tumor boards worldwide publication-title: JCO Precis Oncol – volume: 6 start-page: 2013 ident: 2022011918031981700_onco13580-bib-0026 article-title: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal publication-title: Sci Signal – ident: 2022011918031981700_onco13580-bib-0033 – volume: 8 start-page: 57845 year: 2017 ident: 2022011918031981700_onco13580-bib-0008 article-title: Implementation and utilization of the molecular tumor board to guide precision medicine publication-title: Oncotarget doi: 10.18632/oncotarget.18471 – volume: 47 start-page: D745 year: 2019 ident: 2022011918031981700_onco13580-bib-0030 article-title: Ensembl 2019 publication-title: Nucleic Acids Res doi: 10.1093/nar/gky1113 – volume: 352 start-page: 728 year: 2007 ident: 2022011918031981700_onco13580-bib-0038 article-title: Characterization of a novel oncogenic K-ras mutation in colon cancer publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2006.11.091 – volume: 1 year: 2017 ident: 2022011918031981700_onco13580-bib-0007 article-title: Personalized medicine in the oncology clinic: Implementation and outcomes of the Johns Hopkins molecular tumor board publication-title: JCO Precis Oncol – volume: 121 start-page: 34 year: 2019 ident: 2022011918031981700_onco13580-bib-0003 article-title: Molecular tumour boards and molecular diagnostics for patients with cancer in The Netherlands: Experiences, challenges, and aspirations publication-title: Br J Cancer doi: 10.1038/s41416-019-0489-3 – volume: 7 start-page: 24860 year: 2016 ident: 2022011918031981700_onco13580-bib-0009 article-title: Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer publication-title: Oncotarget doi: 10.18632/oncotarget.8391 – volume: 3 year: 2018 ident: 2022011918031981700_onco13580-bib-0015 article-title: Multidisciplinary molecular tumour board: A tool to improve clinical practice and selection accrual for clinical trials in patients with cancer publication-title: ESMO Open doi: 10.1136/esmoopen-2018-000398 – ident: 2022011918031981700_onco13580-bib-0036 – volume: 22 start-page: 144 year: 2017 ident: 2022011918031981700_onco13580-bib-0010 article-title: Key lessons learned from Moffitt's molecular tumor board: The Clinical Genomics Action Committee experience publication-title: The Oncologist doi: 10.1634/theoncologist.2016-0195 – volume: 10 start-page: 4 year: 2016 ident: 2022011918031981700_onco13580-bib-0031 article-title: The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies publication-title: Hum Genomics doi: 10.1186/s40246-016-0061-7 – volume: 526 start-page: 68 year: 2015 ident: 2022011918031981700_onco13580-bib-0025 article-title: A global reference for human genetic variation publication-title: Nature doi: 10.1038/nature15393 – volume: 31 start-page: 1806 year: 2013 ident: 2022011918031981700_onco13580-bib-0001 article-title: Genomics-driven oncology: Framework for an emerging paradigm publication-title: J Clin Oncol doi: 10.1200/JCO.2012.46.8934 – volume: 2017 start-page: 513 year: 2017 ident: 2022011918031981700_onco13580-bib-0032 article-title: OncoKB: A precision oncology knowledge base publication-title: JCO Precis Oncol – volume: 5 start-page: 265 year: 2017 ident: 2022011918031981700_onco13580-bib-0012 article-title: Precision medicine in children and young adults with hematologic malignancies and blood disorders: The Columbia University experience publication-title: Front Pediatr doi: 10.3389/fped.2017.00265 – volume: 19 start-page: 4 year: 2017 ident: 2022011918031981700_onco13580-bib-0042 article-title: Standards and guidelines for the interpretation and reporting of sequence variants in cancer: A joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists publication-title: J Mol Diagn doi: 10.1016/j.jmoldx.2016.10.002 – volume: 45 start-page: D777 year: 2017 ident: 2022011918031981700_onco13580-bib-0028 article-title: COSMIC: Somatic cancer genetics at high-resolution publication-title: Nucleic Acids Res doi: 10.1093/nar/gkw1121 – volume: 28 start-page: 3070 year: 2017 ident: 2022011918031981700_onco13580-bib-0002 article-title: Molecular tumor boards: Current practice and future needs publication-title: Ann Oncol doi: 10.1093/annonc/mdx528 – volume: 4 year: 2019 ident: 2022011918031981700_onco13580-bib-0013 article-title: Prospective analysis of 895 patients on a UK genomics review board publication-title: ESMO Open doi: 10.1136/esmoopen-2018-000469 – volume-title: Code of Conduct for Medical Research year: 2004 ident: 2022011918031981700_onco13580-bib-0022 – volume: 4 start-page: 393 year: 2020 ident: 2022011918031981700_onco13580-bib-0004 article-title: Relevance and effectiveness of molecular tumor board recommendations for patients with non–small-cell lung cancer with rare or complex mutational profiles publication-title: JCO Precis Oncol doi: 10.1200/PO.20.00008 – volume: 20 start-page: 1011 year: 2015 ident: 2022011918031981700_onco13580-bib-0017 article-title: Implementation of a molecular tumor board: The impact on treatment decisions for 35 patients evaluated at Dartmouth-Hitchcock Medical Center publication-title: The Oncologist doi: 10.1634/theoncologist.2015-0097 – volume: 3 year: 2018 ident: 2022011918031981700_onco13580-bib-0005 article-title: Relevance of a molecular tumour board (MTB) for patients’ enrolment in clinical trials: Experience of the Institut Curie publication-title: ESMO Open doi: 10.1136/esmoopen-2018-000339 – volume: 63 start-page: 1368 year: 2016 ident: 2022011918031981700_onco13580-bib-0014 article-title: Integrating genomics into clinical pediatric oncology using the molecular tumor board at the Memorial Sloan Kettering Cancer Center publication-title: Pediatr Blood Cancer doi: 10.1002/pbc.26002 – volume: 102 start-page: 693 year: 2010 ident: 2022011918031981700_onco13580-bib-0039 article-title: Activating K-Ras mutations outwith “hotspot” codons in sporadic colorectal tumours - implications for personalised cancer medicine publication-title: Br J Cancer doi: 10.1038/sj.bjc.6605534 – ident: 2022011918031981700_onco13580-bib-0040 – volume: 48 start-page: 786 year: 2018 ident: 2022011918031981700_onco13580-bib-0011 article-title: Exploring the feasibility and utility of exome-scale tumour sequencing in a clinical setting publication-title: Intern Med J doi: 10.1111/imj.13806 – volume: 574 start-page: 127 year: 2019 ident: 2022011918031981700_onco13580-bib-0024 article-title: The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs publication-title: Nature doi: 10.1038/s41586-019-1600-x – ident: 2022011918031981700_onco13580-bib-0037 |
| SSID | ssj0015932 |
| Score | 2.4986682 |
| Snippet | Background
Molecular tumor boards (MTBs) provide rational, genomics‐driven, patient‐tailored treatment recommendations. Worldwide, MTBs differ in terms of... Molecular tumor boards (MTBs) provide rational, genomics-driven, patient-tailored treatment recommendations. Worldwide, MTBs differ in terms of scope,... Background. Molecular tumor boards (MTBs) provide rational, genomics-driven, patient-tailored treatment recommendations. Worldwide, MTBs differ in terms of... Worldwide, molecular tumor boards (MTBs) differ in terms of scope, composition, methods, and recommendations. This article assesses differences in methods and... |
| SourceID | pubmedcentral proquest gale pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | e1347 |
| SubjectTerms | Biotechnology industry Cancer Cancer Diagnostics and Molecular Pathology Cancer patients Care and treatment Comparative analysis Decision making Gene mutations Genomics Health aspects Humans Medical colleges Methods Molecular diagnostics Molecular targeted therapy Molecular tumor board Multidisciplinary Neoplasms - drug therapy Neoplasms - genetics Netherlands Pathology, Molecular Patient outcomes Pharmaceutical industry Physicians Rare mutations |
| Title | Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fonco.13580 https://www.ncbi.nlm.nih.gov/pubmed/33111480 https://www.proquest.com/docview/2455179417 https://pubmed.ncbi.nlm.nih.gov/PMC8342588 |
| Volume | 26 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3da9swEBelhbKX0X10Sz-GxgalI6ax5Y_z2EuXtZRBmj6kkDdhfdFAY5ek-Sv6T-9Odty4jMFejI3OQpbupDvf3e8Y--pyY1WmXeDw7A3iXOugiIsi0NaZFHII05wSnEfX6dVt_HuaTLfYj3UuTI0P0f5wI8nw-zUJeKGWZ8-goVWpK6raAGiw76BWL4i_o_im9SEkuah9nSCCDJ9acNLo7PndznH0clPeOJVeRkxuarL-KLrcY68bHZKf14v-hm3Z8i3bHTVe8nfsyWfVUid2wYdtoUFeOT5aV8Plk9W8WvCfFSVd8VnJkV_4Rvbvd_7LulnpA7r6vpMmuqvPR77o9LLPkY5PfCS5NfQ-wRNwsmfnc9vUalq-Z7eXF5PhVdAUXQg0VRAK0MAJEw1ppsAkqSMFIidIeJMnStgUiiRzMRSWVEdrinBgUcFIDSoqKgQQRuyz7bIq7UfGlXJaDcCoUKAZZwwygTEidRAZBwlAj52u517qBpGcCmPcyxpLOZK0TtKvU499aWkfahyOv1Kd0BJKEk7sSRdNjgGOh2Cu5HkG5KnNB6LHjjqUKFS60_x5zQSSmigSrbTVaimjOCFUszjMeuxDzRTtgIQIybzEYWQddmkJCMu721LO7jymNwjcPGlKvnnG-sc3yvH1cOzvDv6H-JC9iigcx8cuHrHtx8XKHqM-9ag-ebHB62Q8_QPeih8o |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3da9swEBelg24vY91X07WdRgdjI6axZcvnvnXZSvrhdA8p9E1YXyzQ2CNp_or-09XJjhuXMdibjc5Clu6kO93d7wj5bDNtZKpsYN3ZG8SZUkERF0WgjNUcMgh5hgnO-ZiPruPzm-Smic3BXJgaH6K9cEPJ8Ps1CjheSB89ooZWpaqwbAM4i_1ZzJ3tgsDO8a_WiZBkrHZ2AgtS99aik0ZHj992zqOnu_LasfQ0ZHJdlfVn0ekr8rJRIulJverbZMOUr8lW3rjJ35B7n1aLnZg5HbaVBmllab4qh0sny1k1p98rzLqi05I6hqFr6b_H9Iex09JHdPV9J014V5_mvur0ok8dHZ34UHKj8XvEJ6Bo0M5mpinWtHhLrk9_ToajoKm6ECgsIRQ4CydMFPBUgk64RQ0iQ0x4nSWSGQ5FktoYCoO6o9FFODBOw-DaaSoyBGCavSObZVWaHUKltEoOQMuQOTtOa8cFWjNuIdIWEoAe-bqae6EaSHKsjHErajDlSOA6Cb9OPXLY0v6pgTj-SvUFl1CgdLqeVNEkGbjxIM6VOEkBXbXZgPXIXofSSZXqNH9aMYHAJgxFK021XIgoThDWLA7THnlfM0U7IMZCtC_dMNIOu7QECObdbSmnvz2oNzC3e-KUfPOM9Y9_FFfj4ZV_2v0f4o_k-WiSX4rLs_HFB_IiwtgcH8i4Rzbv5kuz75SrO3ngRegBdiohcg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3da9swED9KB2UvY-u-snatxgZjI6ax5Q959KVLF7qPpH1IoW_C-qKBxi5J81fsn96d7LhxGYO92egkZOlOuvPd_Q7gg8uNVZl2gcO7N4hzrYMiLopAW2dSkYswzSnBeTxJzy7jH1fJ1RYcr3NhanyI9ocbSYY_r0nAb407ugcNrUpdUdUGgQb7oxgZj_g7ii9aH0KS89rXKXiQ4VsLThod3fftXEcPD-WNW-lhxOSmJuuvotFTeNLokOyk3vRnsGXLXdgZN17y5_DbZ9XSIHbBhm2hQVY5Nl5Xw2XT1bxasK8VJV2xWcmQX9hG9u8XdmrdrPQBXX0_SBPd1WdjX3R62WdIx6Y-ktwa6k_wBIzs2fncNrWali_gcvRtOjwLmqILgaYKQgEaOGGiRZopYZLUkQKREyS8yRPFbSqKJHOxKCypjtYU4cCigpEaVFRUKAQ3_CVsl1VpXwNTymk1EEaFHM04Y5AJjOGpE5FxIhGiB5_Way91g0hOhTFuZI2lHEnaJ-n3qQfvW9rbGofjr1QfaQslCSeOpIsmxwDnQzBX8iQT5KnNB7wH-x1KFCrdaX63ZgJJTRSJVtpqtZRRnBCqWRxmPXhVM0U7Ic5DMi9xGlmHXVoCwvLutpSza4_pLTgenrQknz1j_eMb5flkeO6f3vwP8SHsXJyO5K_vk5978DiiyBwfxrgP23eLlX2LqtWdOvAS9AfLaiCt |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Multicenter+Comparison+of+Molecular+Tumor+Boards+in+The+Netherlands%3A+Definition%2C+Composition%2C+Methods%2C+and+Targeted+Therapy+Recommendations&rft.jtitle=The+oncologist+%28Dayton%2C+Ohio%29&rft.au=Koopman%2C+Bart&rft.au=Groen%2C+Harry+J+M&rft.au=Ligtenberg%2C+Marjolijn+J+L&rft.au=Gr%C3%BCnberg%2C+Katrien&rft.date=2021-08-01&rft.eissn=1549-490X&rft.volume=26&rft.issue=8&rft.spage=e1347&rft_id=info:doi/10.1002%2Fonco.13580&rft_id=info%3Apmid%2F33111480&rft.externalDocID=33111480 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1083-7159&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1083-7159&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1083-7159&client=summon |